K, Ozaki Y, Ismail TF, et al. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter‐IVUS. JACC Cardiovasc Imaging 2012; 5(2): 169–177.36 36 Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography. J Am Coll Cardiol 2014; 64(21): 2207–2217.
37 37 Tian J, Hou J, Xing L, et al. Does neovascularization predict response to statin therapy? Optical coherence tomography study. Int J Cardiol 2012; 158(3): 469–470.
38 38 Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid‐lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291(9): 1071–1080.
39 39 Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high‐intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295(13): 1556–1565.
40 40 Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365(22): 2078–2087.
41 41 Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER steering committee and investigators. Evolocumab and clinical Outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376:1713–22
42 42 Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES committees and investigators. Alirocumab and cardiovascular Outcomes after acute coronary syndrome. N Engl J Med. 2018; 379:2097–107.
43 43 Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin‐treated patients: the GLAGOV randomized clinical trial. JAMA. 2016; 316(22):2373–2384
44 44 Ino Y, Kubo T, Tanaka A, et al. Difference of culprit lesion morphologies between ST‐segment elevation myocardial infarction and non‐ST‐segment elevation acute coronary syndrome: an optical coherence tomography study. JACC Cardiovasc Interv 2011; 4(1): 76–82.
45 45 Shimamura K, Ino Y, Kubo T, et al. Difference of ruptured plaque morphology between asymptomatic coronary artery disease and non‐ST elevation acute coronary syndrome patients: an optical coherence tomography study. Atherosclerosis 2014; 235(2): 532–537.
46 46 Otsuka F, Joner M, Prati F, et al. Clinical classification of plaque morphology in coronary disease. Nat Rev Cardiol 2014; 11(7): 379–389.
47 47 Jia H, Abtahian F, Aguirre AD, et al. in vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol 2013; 62: 1748–1758.
48 48 Sugiyama T, Yamamoto E, Bryniarski K,. Nonculprit plaque characteristics in patients with acute coronary syndrome caused by plaque erosion vs plaque rupture: a 3‐vessel optical coherence tomography study erosion vs rupture nonculprit plaque morphology in acute coronary syndrome erosion vs rupture nonculprit plaque morphology in acute coronary syndrome. JAMA Cardiol 2018; 3:207–214.
49 49 Dai J, Xing L, Jia H, et al. in vivo predictors of plaque erosion in patients with ST‐segment elevation myocardial infarction: a clinical, angiographical, and intravascular optical coherence tomography study. Eur Heart J 2018; 39:2077–2085.
50 50 Prati F, Uemura S, Souteyrand G, et al. OCT‐based diagnosis and management of STEMI associated with intact fibrous cap. JACC Cardiovasc Imaging 2013; 6(3): 283–287.
51 51 Kubo T, Akasaka T, Shite J, et al. OCT compared with IVUS in a coronary lesion assessment: the OPUS‐CLASS study. JACC Cardiovasc Imaging 2013; 6(10): 1095–1104.
52 52 Habara M, Nasu K, Terashima M, et al. Impact of frequency‐domain optical coherence tomography guidance for optimal coronary stent implantation in comparison with intravascular ultrasound guidance. Circ Cardiovasc Interv 2012; 5(2): 193–201.
53 53 Liu Y, Shimamura K, Kubo T, et al. Comparison of longitudinal geometric measurement in human coronary arteries between frequency‐domain optical coherence tomography and intravascular ultrasound. Int J Cardiovasc Imaging 2014; 30(2): 271–277.
54 54 Prati F, Di Vito L, Biondi‐Zoccai G, et al. Angiography alone versus angiography plus optical coherence tomography to guide decision‐making during percutaneous coronary intervention: the Centro per la Lotta contro l’Infarto‐Optimisation of Percutaneous Coronary Intervention (CLI‐OPCI) study. EuroIntervention 2012; 8(7): 823–829.
55 55 Burzotta F, Leone AM, Aurigemma C, et al. Fractional Flow Reserve or Optical Coherence Tomography to Guide Management of Angiographically Intermediate Coronary Stenosis: A Single‐Center Trial. JACC Cardiovasc Interv. 2020 Jan 13; 13(1):49–58. doi: 10.1016/j.jcin.2019.09.034.
56 56 Ali ZA, Maehara A, Ge´ne´reux P, et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: oPTIMIZE PCI): a randomised controlled trial. The Lancet 2016; 388:2618–2628.
57 57 Kubo T, Shinke T, Okamura T, et al. Optical frequency domain imaging vs intravascular ultrasound in percutaneous coronary intervention (OPINION trial): one‐year angiographic and clinical results. Eur Heart J 2017; 38:3139–3147.
58 58 Buccheri S, Franchina G, Romano S, et al. Clinical outcomes following intravascular imaging‐guided versus coronary angiography‐guided percutaneous coronary intervention with stent implantation: a systematic review and Bayesian network meta‐analysis of 31 studies and 17 882 patients. JACC Cardiovasc Interv 2017; 10:2488–2498.
59 59 Moussa I, Moses J, Di Mario C, et al. Does the specific intravascular ultrasound criterion used to optimize stent expansion have an impact on the probability of stent restenosis? Am J Cardiol 1999; 83:1012–7.
60 60 Kang SJ, Ahn JM, Song H, et al. Comprehensive intravascular ultrasound assessment of stent area and its impact on restenosis and adverse cardiac events in 403 patients with unprotected left main disease. Circ Cardiovasc Interv 2011; 4: 562–9.
61 61 Doi H, Maehara A, Mintz GS, et al. Impact of post‐intervention minimal stent area on 9‐month follow‐up patency of paclitaxel‐eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. J Am Coll Cardiol Intv 2009; 2:1269–75.
62 62 Song HG, Kang SJ, Ahn JM, et al. Intravascular ultrasound assessment of optimal stent area to prevent in‐stent restenosis after zotarolimus‐, everolimus‐, and sirolimus‐eluting stent implantation. Catheter Cardiovasc Interv 2014; 83:873–8.
63 63 Choi SY, Maehara A, Cristea E, et al. Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS‐AMI) substudy. Am J Cardiol 2012; 109:455–60.
64 64 Fujii K, Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus‐eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2005; 45: 995–8.
65 65 Liu X, Doi H, Maehara A, et al. A volumetric intravascular ultrasound comparison of early drug eluting stent thrombosis versus restenosis. J Am Coll Cardiol Intv 2009; 5:428–34.
66 66 Choi SY, Witzenbichler B, Maehara A, et al. Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents
